Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND-EC-DCT: 1 vs 2 Years of Maintenance Anti-PD1 in Endometrial Cancer
NCT07867002Phase 3Not yet recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Oct 2026
- Primary completion
- Oct 2032
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab and dostarlimab in endometrial cancer (EC) (2 arms), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Progression Free Survival at 36 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
pembrolizumabdostarlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07867002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07867002.